Cargando…
Drug interaction risk between cardioprotective drugs and drugs used in treatment of COVID-19: A evidence-based review from six databases
BACKGROUND AND AIMS: This Review discusses the potential drug interactions risk between Drugs used in treating COVID-19 infection and Drugs used in treating comorbid conditions (Diabetes, hypertension, cardiovascular illness). METHOD: Six Databases were consulted a) Micromedex drug interaction b) Me...
Autores principales: | S K, Shini Rubina, P A, Anuba, B, Swetha, kalala, Kavya Priya, PM, Aishwarya, Sabarathinam, Sarvesh |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Diabetes India. Published by Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8898923/ https://www.ncbi.nlm.nih.gov/pubmed/35279008 http://dx.doi.org/10.1016/j.dsx.2022.102451 |
Ejemplares similares
-
An exploration of the experience of dapagliflozin in clinical practice
por: Anitha, Anuba Paulvarnan, et al.
Publicado: (2022) -
Bempedoic acid: A nonstatin drug for the management of hypercholesterolemia
por: Govindaraju, Asvitha, et al.
Publicado: (2021) -
Association Between Monocyte-to-High-Density Lipoprotein (HDL) Cholesterol Ratio and Proteinuria in Patients With Type 2 Diabetes Mellitus: A Prospective Observational Study
por: D, Yashilha, et al.
Publicado: (2023) -
CYP3A4 mediated pharmacokinetics drug interaction potential of Maha-Yogaraj Gugglu and E, Z guggulsterone
por: Sabarathinam, Sarvesh, et al.
Publicado: (2021) -
Clinical Pharmacokinetic Drug Interaction Potential of MenoAct851 in Adult, Female Healthy Volunteers
por: Thangavel Mahalingam, Vijayakumar, et al.
Publicado: (2020)